JNJ-38518168 30 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

HealthyPsoriasis

Phase 1

Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers

CompletedNCT01690286

Janssen Research & Development, LLCHealthy

Start: 2012-10-31End: 2012-12-31Updated: 2013-07-16

Phase 2

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

CompletedNCT02295865

Janssen Research & Development, LLCPsoriasis

Start: 2014-11-17End: 2016-03-11Updated: 2017-07-07